Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting ...Middle East

– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – – 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in...

Hence then, the article about syndax presents positive revuforj revumenib data in acute leukemias from multiple trials including the save combination and augment 101 trials at 66th ash annual meeting was published today ( Sunday 08/12/2024 - 02:24 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting )

Also on site :

• Starbucks’ New ChatGPT Integration Is a Potential Privacy Nightmare
• Trader Joe's $4 Find Has Returned — Why Fans Obsess Over the Easy Dinner
• 1980s Rock Band Announces Brand New Album but There's a Twist